Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population: Real-World Use and Early Medication Success

References

• Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2023. Available from: file:///C:/Users/Ruth%20Murray/Downloads/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf. Accessed March, 2024.
   Google Scholar
• Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–458. doi:10.1016/S2213-2600(21)00511-7
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chronic obstructive pulmonary disease. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed March, 2024.
   Google Scholar
• McLean S, Hoogendoorn M, Hoogenveen RT, et al. Projecting the COPD population and costs in England and Scotland: 2011 to 2030. Sci Rep. 2016;6:31893. doi:10.1038/srep31893
   PubMed Web of Science ®Google Scholar
• Murray CJL, Richards MA, Newton JN, et al. UK health performance: findings of the global burden of disease study 2010. Lancet. 2013;381(9871):997–1020. doi:10.1016/S0140-6736(13)60355-4
   PubMed Web of Science ®Google Scholar
• Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524. doi:10.1177/1753465817750524
   Web of Science ®Google Scholar
• Krishnan S, Tan WC, Farias R, et al. Impaired spirometry and COPD increase the risk of cardiovascular disease: a Canadian cohort study. Chest. 2023;164(3):637–649. doi:10.1016/j.chest.2023.02.045
   PubMed Web of Science ®Google Scholar
• Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi:10.1016/S2213-2600(15)00241-6
   PubMed Web of Science ®Google Scholar
• McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax. 2007;62(5):411–415. doi:10.1136/thx.2006.072348
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Dickens AP, Skinner D, et al. Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study. Lancet Reg Health Eur. 2023;29:100619. doi:10.1016/j.lanepe.2023.100619
   PubMedGoogle Scholar
• Breztri/Trixeo summary of product characteristics. European Medicines Compendium. Available from: https://www.medicines.org.uk/emc/product/12028/smpc#about-medicine. Accessed March, 2024.
   Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-8
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced All-cause mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for COPD: a randomized, double-blind, multi-center parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. doi:10.1164/rccm.202006-2618OC
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Kerkhof M, Soriano JB, Mikkelsen H, Price DB. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res. 2016;17(1):120. doi:10.1186/s12931-016-0433-5
   PubMed Web of Science ®Google Scholar
• Roche N, Campbell JD, Krishnan JA, et al. Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the respiratory effectiveness group-European Academy of Allergy and Clinical Immunology Task Force. Clin Transl Allergy. 2019;9:20. doi:10.1186/s13601-019-0255-x
   PubMed Web of Science ®Google Scholar
• Roche N, Reddel HK, Agusti A, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med. 2013;1(10):e29–30. doi:10.1016/S2213-2600(13)70199-1
   PubMed Web of Science ®Google Scholar
• EMA calls for high-quality observational research in context of COVID-19; 2020. Available from: https://www.ema.europa.eu/en/news/ema-calls-high-quality-observational-research-context-covid-19. Accessed March, 2024.
   Google Scholar
• Usmani OS, Bosnic-Anticevich S, Dekhuijzen R, et al. Real-world impact of nonclinical inhaler regimen switches on asthma or COPD: a systematic review. J Allergy Clin Immunol Pract. 2022;10(10):2624–2637. doi:10.1016/j.jaip.2022.05.039
   PubMed Web of Science ®Google Scholar
• Optimum patient care research database. Available from: https://opcrd.co.uk/. Accessed March, 2024.
   Google Scholar
• Lynam A, Curtis C, Stanley B, et al. Data-resource profile: United Kingdom optimum patient care research database. Pragmat Obs Res. 2023;14:39–49. doi:10.2147/POR.S395632
   PubMed Web of Science ®Google Scholar
• Campbell JD, Perry R, Papadopoulos NG, et al. The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. Clin Transl Allergy. 2019;9:21. doi:10.1186/s13601-019-0256-9
   PubMed Web of Science ®Google Scholar
• European network of centres for pharmacology and pharmacovigilance. Available from: http://www.encepp.eu/. Accessed March, 2024.
   Google Scholar
• Pullen R, Miravitlles M, Sharma A, et al. CONQUEST quality standards: for the collaboration on quality improvement initiative for achieving excellence in standards of COPD care. Int J COPD. 2021;16:2301–2322.
   Google Scholar
• Price DB, Henley W, Cançado JED, et al. Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone. Int J Chron Obstruct Pulmon Dis. 2022;17:355–370. doi:10.2147/COPD.S342357
   PubMed Web of Science ®Google Scholar
• Park HS, Yoon D, Lee HY, et al. Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA. Respirology. 2019;24(10):972–979. doi:10.1111/resp.13559
   PubMed Web of Science ®Google Scholar
• Wan Yau Ming S, Haughney J, Small I, et al. Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: a real-life effectiveness and cost impact evaluation. Respir Med. 2017;129:199–206. doi:10.1016/j.rmed.2017.06.016
   PubMed Web of Science ®Google Scholar
• Strange C, Tkacz J, Schinkel J, et al. Exacerbations and real-world outcomes after single-inhaler triple therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: results from the EROS (US) Study. Int J Chron Obstruct Pulmon Dis. 2023;18:2245–2256. doi:10.2147/COPD.S432963
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: real-World Comparative Effectiveness and Safety. Int J Chron Obstruct Pulmon Dis. 2022;17:1975–1986. doi:10.2147/COPD.S378486
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Joksaite S, Sansbury LB, Compton C, Di Boscio V, Ismaila AS. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. Int J Chron Obstruct Pulmon Dis. 2022;17:1455–1466. doi:10.2147/COPD.S338436
   PubMed Web of Science ®Google Scholar
• Madawala S, Quach A, Lim JY, et al. Healthcare experience of adults with COPD during the COVID-19 pandemic: a rapid review of international literature. BMJ Open Respir Res. 2023;10(1). doi:10.1136/bmjresp-2022-001514
   PubMed Web of Science ®Google Scholar
• Bazell C, Pollack M, Comellas AP, et al. A 4-year retrospective claims analysis of oral corticosteroid use and health conditions in newly diagnosed medicare FFS Patients with COPD. Int J Chron Obstruct Pulmon Dis. 2022;17:2635–2652. doi:10.2147/COPD.S373590
   PubMed Web of Science ®Google Scholar
• Tse G, Emmanuel B, Ariti C, et al. A long-term study of adverse outcomes associated with oral corticosteroid use in COPD. Int J COPD. 2023;18:2565–2580.
   Google Scholar
• Janson C, Wiklund F, Telg G, Stratelis G, Sandelowsky H. High use of short-acting β(2)-agonists in COPD is associated with an increased risk of exacerbations and mortality. ERJ Open Res. 2023;9(3):00722–02022. doi:10.1183/23120541.00722-2022
   PubMedGoogle Scholar
• Jones RCM, Price D, Ryan D, et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 2014;2(4):267–276. doi:10.1016/S2213-2600(14)70008-6
   PubMed Web of Science ®Google Scholar
• Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D. Distribution, temporal stability and appropriateness of therapy of patients With COPD in the UK in Relation to GOLD 2019. EClinicalMedicine. 2019;14:32–41. doi:10.1016/j.eclinm.2019.07.003
   PubMedGoogle Scholar
• Sinha IP, Calvert J, Hickman KC, et al. National Asthma and COPD Audit Programme and the NHS Long Term Plan. Lancet Respir Med. 2019;7(10):841. doi:10.1016/S2213-2600(19)30258-9
   PubMed Web of Science ®Google Scholar
• NHS Wales. Health in wales: chronic obstructive pulmonary disease; 2018. Available from: https://awttc.nhs.wales/files/guidelines-and-pils/all-wales-copd-management-and-prescribing-guideline-pdf/. Accessed March, 2024.
   Google Scholar
• The Scotish Government. COPD best practice guide; 2017. Available from: https://www.gov.scot/binaries/content/documents/govscot/publications/advice-and-guidance/2017/11/copd-best-practice-guide/documents/00527135-pdf/00527135-pdf/govscot%3Adocument/00527135.pdf. Accessed March, 2024.
   Google Scholar
• Strengthening and reporting of observational studies in epidemiology. Available from: https://www.strobe-statement.org/. Accessed March, 2024.
   Google Scholar
• Podubinski T, Townsin L, Thompson SC, Tynan A, Argus G. Experience of healthcare access in Australia during the first year of the COVID-19 pandemic. Int J Environ Res Public Health. 2021;18(20). doi:10.3390/ijerph182010687
   Web of Science ®Google Scholar